Clinical trials: Hantavirus Infections
Hantavirus Pulmonary Infection, Immunisation
Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection Delivery Device
This is a Phase 1, randomized, placebo controlled, double-blind, dose escalation trial of 48 males and non-pregnant females, 18-49 years old, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03682107
- Testing
- Andes virus DNA vaccine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Signs and Symptoms, Fever
Biomedical Signal Extraction From Symptom Descriptions: An Observational Registry Using the OpenGenome Platform
This registry prospectively collects anonymized free-text symptom descriptions submitted voluntarily by adults through the OpenGenome platform at opengenome.bio.
- Conditions
- Signs and Symptoms, Fever, Myalgia, Skin Diseases
- Trial name
- OGNOME-REG (NCT07578610)
- Testing
- OpenGenome AI Platform
- Where
- Germany
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- OpenGenome
Hemorrhagic Fever With Renal Syndrome
Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever
The purpose of this study is to compare the immune responses of two different doses (1.0 mg and 2.0 mg) and two different dosing schedules (two doses or three doses) of a mixed Hantaan virus (HTNV) and Puumala virus (PUUV) DNA…
- Trial name
- NCT02116205
- Testing
- HTNV/PUUV DNA vaccine, TriGrid Delivery System (TDS)
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Hantaan Virus Nephropathy, Puumala Virus Nephropathy
Safety/Immunogenicity Hantaan Virus DNA Vaccine and Puumala Virus DNA Vaccine, For Prevention of HFRS
A randomized 4 cohort study that is comparing the data collected during the earlier phase study and to determine if immunogenicity can be retained with a 1 mg dose of Hantaan DNA vaccine.
- Trial name
- NCT04333459
- Testing
- Hantaan DNA Vaccine/Puumala DNA Vaccine
- Where
- 2 sites in United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Hemorrhagic Fever With Renal Syndrome
Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines
The purpose of this study is: To assess safety and tolerability of the HTNV and PUUV DNA vaccines, pWRG/HTN-M(x) and pWRG/PUUV-M(s2), administered intramuscularly using a TDS-IM electroporation device Secondary: To evaluate…
- Trial name
- HTNV/PUUV (NCT01502345)
- Testing
- Vaccine/device combination for prevention of HFRS
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Hantaan Virus Disease, Puumala Virus
Combination HTNV and PUUV DNA Vaccine
To evaluate the safety and reactogenicity of the hantaan virus (HTNV), puumala virus (PUUV), and combination HTNV/PUUV DNA vaccine candidates delivered to healthy adults
- Trial name
- NCT03718130
- Testing
- Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID), Hantaan virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM), Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge